USPTO Patent Grant US12583844B2, titled 'Hydantoin MMP inhibitors for disease treatment,' has been issued to Foresee Pharmaceuticals USA, Inc. The patent covers novel hydantoin-based compounds designed to inhibit matrix metalloproteinases (MMPs), with a specific focus on MMP-12. The claims extend to compositions containing these inhibitors and methods for their use in treating a range of diseases, including inflammatory conditions, respiratory diseases, fibrotic disorders, arthritis, cancer, and cardiovascular diseases.

This patent grant signifies the protection of intellectual property related to new therapeutic agents. While it does not impose direct compliance obligations on other entities, it is relevant for pharmaceutical companies and researchers in the organic chemistry and drug development space. Companies developing or researching MMP inhibitors should be aware of this patent to avoid potential infringement and to inform their own R&D strategies.